Omega Therapeutics (OMGA) Competitors $0.55 -0.02 (-3.04%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends OMGA vs. VTYX, IFRX, CRBP, FTLF, NBTX, MNPR, TELO, SLDB, SAVA, and BDTXShould you be buying Omega Therapeutics stock or one of its competitors? The main competitors of Omega Therapeutics include Ventyx Biosciences (VTYX), InflaRx (IFRX), Corbus Pharmaceuticals (CRBP), FitLife Brands (FTLF), Nanobiotix (NBTX), Monopar Therapeutics (MNPR), Telomir Pharmaceuticals (TELO), Solid Biosciences (SLDB), Cassava Sciences (SAVA), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. Omega Therapeutics vs. Ventyx Biosciences InflaRx Corbus Pharmaceuticals FitLife Brands Nanobiotix Monopar Therapeutics Telomir Pharmaceuticals Solid Biosciences Cassava Sciences Black Diamond Therapeutics Ventyx Biosciences (NASDAQ:VTYX) and Omega Therapeutics (NASDAQ:OMGA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking. Is VTYX or OMGA more profitable? Ventyx Biosciences has a net margin of 0.00% compared to Omega Therapeutics' net margin of -902.93%. Ventyx Biosciences' return on equity of -54.94% beat Omega Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ventyx BiosciencesN/A -54.94% -50.01% Omega Therapeutics -902.93%-213.13%-41.24% Which has more risk & volatility, VTYX or OMGA? Ventyx Biosciences has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Omega Therapeutics has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Do institutionals & insiders hold more shares of VTYX or OMGA? 97.9% of Ventyx Biosciences shares are owned by institutional investors. Comparatively, 97.5% of Omega Therapeutics shares are owned by institutional investors. 18.2% of Ventyx Biosciences shares are owned by company insiders. Comparatively, 8.5% of Omega Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer VTYX or OMGA? In the previous week, Ventyx Biosciences had 13 more articles in the media than Omega Therapeutics. MarketBeat recorded 14 mentions for Ventyx Biosciences and 1 mentions for Omega Therapeutics. Ventyx Biosciences' average media sentiment score of 0.66 beat Omega Therapeutics' score of 0.59 indicating that Ventyx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ventyx Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omega Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate VTYX or OMGA? Ventyx Biosciences presently has a consensus target price of $10.00, suggesting a potential upside of 395.05%. Omega Therapeutics has a consensus target price of $9.20, suggesting a potential upside of 1,575.77%. Given Omega Therapeutics' higher probable upside, analysts plainly believe Omega Therapeutics is more favorable than Ventyx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Omega Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has better earnings & valuation, VTYX or OMGA? Omega Therapeutics has higher revenue and earnings than Ventyx Biosciences. Ventyx Biosciences is trading at a lower price-to-earnings ratio than Omega Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVentyx BiosciencesN/AN/A-$192.96M-$2.36-0.86Omega Therapeutics$3.09M9.84-$97.43M-$1.33-0.41 Does the MarketBeat Community believe in VTYX or OMGA? Ventyx Biosciences received 3 more outperform votes than Omega Therapeutics when rated by MarketBeat users. However, 73.68% of users gave Omega Therapeutics an outperform vote while only 46.97% of users gave Ventyx Biosciences an outperform vote. CompanyUnderperformOutperformVentyx BiosciencesOutperform Votes3146.97% Underperform Votes3553.03% Omega TherapeuticsOutperform Votes2873.68% Underperform Votes1026.32% SummaryOmega Therapeutics beats Ventyx Biosciences on 8 of the 15 factors compared between the two stocks. Get Omega Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OMGA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OMGA vs. The Competition Export to ExcelMetricOmega TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.09M$2.96B$5.23B$8.96BDividend YieldN/A1.94%5.13%4.04%P/E Ratio-0.4142.7687.2917.29Price / Sales9.84265.171,255.8979.02Price / CashN/A192.9043.8235.97Price / Book0.523.965.324.79Net Income-$97.43M-$41.02M$122.78M$225.07M7 Day Performance-22.24%-1.80%-0.19%1.51%1 Month Performance-33.86%0.47%3.72%4.68%1 Year Performance-84.66%-1.73%27.31%20.92% Omega Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OMGAOmega Therapeutics2.4893 of 5 stars$0.55-3.0%$9.20+1,575.8%-85.7%$39.09M$3.09M-0.41120VTYXVentyx Biosciences3.1034 of 5 stars$1.95-6.3%$10.00+412.8%-3.3%$137.89MN/A-0.8330Analyst ForecastAnalyst RevisionNews CoverageIFRXInflaRx2.2989 of 5 stars$2.34+4.9%$8.00+241.9%+56.8%$137.79M$168,498.00-2.1760Analyst ForecastShort Interest ↑News CoverageCRBPCorbus Pharmaceuticals4.217 of 5 stars$11.30-4.2%$62.00+448.7%+93.8%$137.62M$880,000.00-2.4140Short Interest ↓News CoveragePositive NewsFTLFFitLife Brands4.3813 of 5 stars$29.80+0.1%$40.00+34.2%+58.6%$137.02M$62.76M17.6320Short Interest ↓News CoveragePositive NewsNBTXNanobiotix3.0636 of 5 stars$2.90+2.5%$12.00+313.8%-60.9%$136.69M$36.22M0.00100Positive NewsGap UpMNPRMonopar Therapeutics2.9138 of 5 stars$25.69+1.3%$38.50+49.9%+1,203.2%$135.59MN/A-13.0410Short Interest ↑Gap UpTELOTelomir PharmaceuticalsN/A$4.50+9.5%N/AN/A$133.25MN/A0.001Short Interest ↑News CoverageGap UpSLDBSolid Biosciences3.7642 of 5 stars$3.31-10.1%$15.30+362.2%-59.4%$132.25M$8.09M-1.09100Gap DownSAVACassava Sciences4.4431 of 5 stars$2.73-3.5%$111.50+3,984.2%-89.2%$131.34MN/A-1.9830BDTXBlack Diamond Therapeutics2.9009 of 5 stars$2.31+19.7%$15.50+571.0%-19.4%$130.71MN/A-1.7490News CoveragePositive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies Ventyx Biosciences Competitors InflaRx Competitors Corbus Pharmaceuticals Competitors FitLife Brands Competitors Nanobiotix Competitors Monopar Therapeutics Competitors Telomir Pharmaceuticals Competitors Solid Biosciences Competitors Cassava Sciences Competitors Black Diamond Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OMGA) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omega Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omega Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
